Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion.
Therion Biologics, in collaboration with Aventis Pasteur, is developing ALVAC-CEA/B7.1, a recombinant, pox virus-based vaccine that targets carcinoembryonic antigen (CEA) found on the surface of lung and colorectal tumor cells, for the potential treatment of lung and colorectal cancer. The vaccine is in phase II clinical trials for these indications.
Ertl
Hildegund C J
HC
Wistar Institute, 3600 Spruce Street, Philadelphia, PA 19104, USA. ertl@wistar.upenn.edu
D000818:Animals; D019496:Cancer Vaccines / Q000378:metabolism / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic / Q000706:statistics & numerical data; D015179:Colorectal Neoplasms / Q000188:drug therapy; D004341:Drug Evaluation / Q000331:legislation & jurisprudence / Q000379:methods; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods*; D014614:Vaccines, Synthetic / Q000378:metabolism / Q000627:therapeutic use*
C404395:ALVAC-CEA vaccine; D019496:Cancer Vaccines; D014614:Vaccines, Synthetic